SCHEMBL16623587

SCHEMBL16623587

N=C(c1ccc(N2CCOCC2)cc1)c1c(Nc2c(F)cccc2F)c(Cl)c[nH]c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.39
MAPK7 Q13164 1/20 0.39
NTRK1 P04629 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 1/20 0.37
ZAP70 P43403 1/20 0.36
CCNT1 O60563 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17849203 0.97 ROCK1 (0.40) ROCK1MAPK7NTRK1JAK2JAK1
SCHEMBL17849217 0.90 DGAT1 (0.33) ROCK1MAPK7NTRK1JAK2JAK1
SCHEMBL17849207 0.89 ROCK1 (0.39) ROCK1MAPK7NTRK1ALDH1A1KDM4E
SCHEMBL17849219 0.89 RAF1 (0.42) ROCK1NTRK1ALDH1A1KDM4EHPGD
SCHEMBL17849202 0.89 SMN1; SMN2 (0.44) MAPK7ALDH1A1KDM4EHPGDMAPT
SCHEMBL17849189 0.88 RAB9A (0.45) NTRK1ALDH1A1KDM4EHPGDNPC1
SCHEMBL17849214 0.87 TYK2 (0.38) ROCK1JAK2TYK2ALDH1A1KDM4E
SCHEMBL17849197 0.85 ALDH1A1 (0.38) MAPK7JAK2TYK2ALDH1A1KDM4E
SCHEMBL17849212 0.85 ITGB3 (0.37) NPC1RAB9A
SCHEMBL17849193 0.84 F10 (0.43) ALDH1A1HPGDMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ROCK1 479/4885MAPK7 82/4885NTRK1 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.